These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20885402)

  • 1. The multiple sclerosis market.
    Huynh T
    Nat Rev Drug Discov; 2010 Oct; 9(10):759-60. PubMed ID: 20885402
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 3. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomic considerations in the treatment of multiple sclerosis.
    Sharac J; McCrone P; Sabes-Figuera R
    Drugs; 2010 Sep; 70(13):1677-91. PubMed ID: 20731475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.
    Bailey B
    Ir J Med Sci; 2011 Jun; 180(2):337-41. PubMed ID: 21293948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 7. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 8. No cash to implement NICE, health authorities tell MPs. The National Institute for Clinical Excellence.
    Burke K
    BMJ; 2002 Feb; 324(7332):258. PubMed ID: 11936127
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence.
    Hartung HP
    Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171
    [No Abstract]   [Full Text] [Related]  

  • 10. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
    Tappenden P; Chilcott JB; Eggington S; Oakley J; McCabe C
    Health Technol Assess; 2004 Jun; 8(27):iii, 1-78. PubMed ID: 15215017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 13. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
    Garattini L; Ghislandi F; Da Costa MR
    Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
    [No Abstract]   [Full Text] [Related]  

  • 15. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 16. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
    Kampman MT; Steffensen LH
    Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.